Perrigo Deal Makes Extraction-Resistant PSE A Two-Player Competition
This article was originally published in The Pink Sheet
Executive Summary
Via Highland Pharmaceuticals agreement, Perrigo snaps up the only tamper-resistant pseudoephedrine formulation still available for licensing. It now goes up against Bayer – but will beat the pharma giant to market.
You may also be interested in...
Perrigo's Rx Business Looks Ready To Sell, Says Hedge Fund Investor
Starboard Value states says Perrigo "severely mismanaged" its entry into branded consumer health through the acquisition of a German firm and showed "misguided confidence" in encouraging shareholders to reject Mylan's tender.
Tamper-Resistant PSE Takes Big Pharma Stage: Bayer Licenses Acura’s Formulation
Bayer gains exclusive worldwide license to Acura Pharmaceuticals’ Impede technology for use in a pseudoephedrine-containing product resistant to extraction to make methamphetamine. The deal is Acura’s first licensing, and the first move toward tamper-resistant PSE by a major pharma firm.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.